Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Viridian Therapeutics Earnings Call: Key Takeaways

Viridian Therapeutics reported a strong LUMVO launch with $24.7 million in revenue, treating over 100 patients in its first quarter, while maintaining a robust $955 million cash position for future pipeline development.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthLUMVO generated $24.7 million in its first quarter of launch.
Mgmt ConfidenceExtremely proud of start; firing on all cylinders; 100% committed.
Demand VisibilityOver 100 patients treated; 60-90 day enrollment-to-infusion timeline; no bolus observed.
Op. LeveragePipeline programs plug into established infrastructure with proven track record.
Vol vs PriceDemand-led growth with over 100 patients completing at least one infusion.
Segment GrowthLUMVO launch exceeded expectations; 2,000 core prescribers write 80% of scripts.
New ClientsReached 90% of covered lives; 30% already have policy coverage.
Capex & Debt$955 million in cash and marketable securities; funded through profitability.
RegulatoryCMS assigned permanent J-code effective January 1, 2027; BLA Q1 2027.
CommentaryStrategy focused on conversion of 2,000 core prescribers in established market.
New LaunchesLUMVO launched; VRGN292 Phase 1 starting; VRGN008 data expected later quarter.

Growth

LUMVO generated $24.7 million net product revenue in its first quarter post-approval.

Outlook

BLA submission for subcutaneous Velisig expected Q1 2027; broad payer coverage in 6-9 months.

Risks

Management used vague language regarding specific market share and exit velocity, citing early launch stages.

Source

The company's earnings call, NASDAQ: VRDN, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Viridian Therapeutics, Inc.\DE: key numbers

Share price
$29.80Close, Nov 16
Market cap
$3.38B
Shares outstanding
113.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Viridian Therapeutics, Inc.\DE

All →
7:33 AM ET 8-K
Clinical Trial Data

Viridian Therapeutics, Inc.\DE Clinical Trial Data

Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.

7:30 AM ET 10-Q
Financial Results ▶ Call

Viridian Therapeutics, Inc.\DE Q3 2026 Results: Net Loss of $101M, Loss Widens

Viridian Therapeutics is transitioning toward commercialization with the submission of a Marketing Authorization Application for veligrotug in Europe and a planned BLA submission for elegrobart in early 2027. The company remains pre-profit, relying on existing cash and anticipated future revenues to fund its clinical pipeline, including new trials for VRDN-292 and its FcRn inhibitor portfolio.

Key figure
Net loss $101M
7:12 AM ET 8-K
Financial Results

Viridian Therapeutics, Inc.\DE Financial Results

Viridian Therapeutics reported third quarter 2026 financial results, highlighted by $24.7 million in net product revenue from the launch of Lumvoa (veligrotug-vvze). The company remains on track for a BLA submission for elegrobart in Q1 2027 and expects Phase 1 data for VRDN-008 in Q4 2026.

“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations. These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization.”

Steve Mahoney, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.